An Analysis of Different Components of a High-Throughput Screening Library

被引:9
作者
Saha, Arjun [1 ]
Varghese, Teena [1 ]
Liu, Annie [1 ]
Allen, Samantha J. [1 ]
Mirzadegan, Taraneh [1 ]
Hack, Michael D. [1 ]
机构
[1] Janssen Pharmaceut Res & Dev, 3210 Merryfield Row, La Jolla, CA 92121 USA
关键词
DRUG DISCOVERY; MOLECULAR COMPLEXITY; BIOLOGICAL-ACTIVITY; COMPOUND LIBRARY; GSK EXPERIENCE; CHEMICAL SPACE; COLLECTION; IDENTIFICATION; DIVERSITY; CHEMISTRY;
D O I
10.1021/acs.jcim.8b00258
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Since many projects at pharmaceutical organizations get their start from a high-throughput screening (HTS) campaign, improving the quality of the HTS deck can improve the likelihood of discovering a high-quality lead molecule that can be progressed to a drug candidate. Over the past decade, Janssen has implemented several strategies for external compound acquisition to augment the screening deck beyond the chemical space and number of molecules synthesized for internal projects. In this report, we analyzed the performance of each of those compound collections in the screening campaigns performed internally within Janssen during the last five years. We classified the screening library into two broad categories: Internal and External. The comparison of the performance of these sets of libraries was done by considering the primary, confirmation, and dose response hit rates. Our analysis revealed that Internal compounds (resulting from numerous medicinal chemistry efforts against diverse protein targets) have higher average confirmation hit rates than External ones; however, actives from both categories show similar probabilities of hitting multiple distinct targets. We also investigated the property landscape of both sets of libraries to identify the key elements which make a difference in these categories of compounds. From this analysis, Janssen aims to understand the descriptor landscape of the compounds with the highest hit rates and to use them for improving its future acquisition strategies as well as to inform our plating strategy.
引用
收藏
页码:2057 / 2068
页数:12
相关论文
共 40 条
[1]  
[Anonymous], 2004, NAT REV DRUG DISCOVE, V3, P375
[2]   Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds [J].
Axerio-Cilies, Peter ;
Castaneda, Ivan P. ;
Mirza, Amin ;
Reynisson, Johannes .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (03) :1128-1134
[3]  
Bender A, 2008, CURR OPIN DRUG DISC, V11, P327
[4]   Stability Through the Ages: The GSK Experience [J].
Blaxill, Zoe ;
Holland-Crimmin, Sue ;
Lifely, Rob .
JOURNAL OF BIOMOLECULAR SCREENING, 2009, 14 (05) :547-556
[5]   Quality assessment and analysis of Biogen Idec compound library [J].
Bowes, Scott ;
Sun, Dongyu ;
Kaffashan, Azita ;
Zeng, Chenhui ;
Chuaqui, Claudio ;
Hronowski, Xiaoping ;
Buko, Alex ;
Zhang, Xin ;
Josiah, Serene .
JOURNAL OF BIOMOLECULAR SCREENING, 2006, 11 (07) :828-835
[6]   Unsupervised data base clustering based on Daylight's fingerprint and Tanimoto similarity: A fast and automated way to cluster small and large data sets [J].
Butina, D .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1999, 39 (04) :747-750
[7]   Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site [J].
Chen, Fan ;
Liu, Jie ;
Huang, Mingfeng ;
Hu, Mengjie ;
Su, Ying ;
Zhang, Xiao-kun .
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (07) :736-741
[8]   Promiscuous Aggregate-Based Inhibitors Promote Enzyme Unfolding [J].
Coan, Kristin E. D. ;
Maltby, David A. ;
Burlingame, Alma L. ;
Shoichet, Brian K. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (07) :2067-2075
[9]  
Dahlin JL, 2014, FUTURE MED CHEM, V6, P1265, DOI [10.4155/fmc.14.60, 10.4155/FMC.14.60]
[10]   Components of successful lead generation [J].
Davis, AM ;
Keeling, DJ ;
Steele, J ;
Tomkinson, NP ;
Tinker, AC .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (04) :421-439